Bal Pharma Stock Screener | Share Price & Fundamental Analysis
BALPHARMA
Pharmaceuticals
Screen Bal Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹73.94
▲
0.69 (0.94%)
Share Price BSE
₹73.91
▲
1.22 (1.68%)
Market Cap
₹116.49 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.52
EPS (TTM)
₹4.54
Dividend Yield
1.60%
Debt to Equity
1.94
52W High
₹122.34
52W Low
₹71.47
Operating Margin
9.00%
Profit Margin
6.02%
Revenue (TTM)
₹83.00
EBITDA
₹9.00
Net Income
₹5.00
Total Assets
₹336.00
Total Equity
₹77.00
Bal Pharma Share Price History - Stock Screener Chart
Screen BALPHARMA historical share price movements with interactive charts. Analyze price trends and patterns.
Bal Pharma Company Profile - Fundamental Screener
Screen Bal Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BALPHARMA shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE083D01012
Bal Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen BALPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 336 | 320 | 313 | 261 | 240 | 238 | 261 | 260 | 233 | 211 |
| Current Assets | 235 | 234 | 228 | 185 | 164 | 157 | 183 | 185 | 165 | 143 |
| Fixed Assets | 87 | 80 | 77 | 67 | 69 | 71 | 70 | 72 | 60 | 56 |
| Liabilities | ||||||||||
| Total Liabilities | 336 | 320 | 313 | 261 | 240 | 238 | 261 | 260 | 233 | 211 |
| Current Liabilities | 39 | 45 | 40 | 36 | 34 | 34 | 38 | 46 | 30 | 45 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 77 | 72 | 64 | 59 | 53 | 45 | 60 | 60 | 60 | 55 |
| Share Capital | 16 | 16 | 16 | 15 | 15 | 14 | 14 | 14 | 14 | 13 |
| Reserves & Surplus | 62 | 56 | 48 | 43 | 38 | 38 | 53 | 51 | 48 | 40 |
Screen BALPHARMA income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83 | 67 | 75 | 97 | 75 | 74 | 74 | 83 | 71 | 93 | 82 | 78 | 70 | 75 | 77 |
| Expenses | 74 | 60 | 68 | 85 | 68 | 66 | 65 | 74 | 64 | 85 | 74 | 71 | 65 | 70 | 71 |
| EBITDA | 9 | 7 | 7 | 12 | 7 | 8 | 8 | 8 | 7 | 8 | 8 | 7 | 5 | 6 | 7 |
| Operating Profit % | 9.00% | 9.00% | 8.00% | 10.00% | 9.00% | 10.00% | 11.00% | 10.00% | 9.00% | 8.00% | 10.00% | 5.00% | 7.00% | 8.00% | 8.00% |
| Depreciation | 2 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 3 | 2 | 2 | 2 | 3 |
| Interest | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 3 | 2 | 3 | 3 |
| Profit Before Tax | 3 | 0 | 1 | 6 | 1 | 1 | 1 | 2 | 0 | 2 | 1 | 2 | 1 | 1 | 1 |
| Tax | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Net Profit | 5 | 0 | 1 | 6 | 0 | 1 | 1 | 2 | 0 | 1 | 1 | 2 | 0 | 0 | 1 |
| EPS | 3.40 | 0.13 | 0.45 | 3.73 | 0.16 | 0.65 | 0.33 | 1.03 | 0.06 | 0.62 | 0.54 | 1.33 | 0.19 | 0.08 | 0.38 |
Bal Pharma Cash Flow Screener - Liquidity Fundamentals
Screen BALPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 20 | 23 | -2 | 27 | 22 | 23 | 8 | 1 | 6 | -19 |
| Investing Activities | -15 | -19 | -22 | -10 | -6 | -5 | -8 | -4 | -8 | -14 |
| Financing Activities | -8 | -1 | 24 | -17 | -17 | -20 | 0 | 4 | -6 | 32 |
| Net Cash Flow | -2 | 3 | 0 | 0 | 0 | -2 | 0 | 1 | -8 | -1 |
Screen BALPHARMA shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 50.86% | 50.86% | 50.86% | 51.23% | 51.23% | 50.86% | 50.86% | 51.61% |
| FII Holding | 0.22% | 0.15% | 0.14% | 0.13% | 0.13% | 0.13% | 0.14% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 32.97% | 32.41% | 32.49% | 32.15% | 32.36% | 33.15% | 32.57% | 32.07% |
| Other Holding | 15.94% | 16.58% | 16.51% | 16.49% | 16.28% | 15.86% | 16.43% | 16.32% |
| Shareholder Count | 15,774 | 15,826 | 15,723 | 14,772 | 15,014 | 16,007 | 15,667 | 16,029 |
Bal Pharma Dividend Screener - Share Yield Analysis
Screen BALPHARMA dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2025-March | ₹1.20 | 1.62% |
| 2024-March | ₹1.20 | 1.43% |
| 2023-March | ₹1.00 | 1.10% |
| 2022-March | ₹1.00 | 1.55% |
| 2021-March | ₹1.00 | 0.93% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹1.00 | 3.13% |
| 2018-March | ₹1.00 | 1.43% |
| 2017-March | ₹1.00 | 1.30% |
| 2016-March | ₹0.00 | 0.00% |
Bal Pharma Index Membership - Market Screener Classification
Screen BALPHARMA by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Bal Pharma Market Events Screener - Corporate Actions
Screen BALPHARMA market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 1.20 /share | -6.50% | ||
| Dividend | ₹ 1.00 /share | -1.36% | ||
| Dividend | ₹ 1.00 /share | 10.53% | ||
| Dividend | ₹ 1.00 /share | 6.91% | ||
| Dividend | ₹ 1.20 /share | 31.47% | ||
| Annual General Meeting | NA | 14.26% | ||
| Annual General Meeting | NA | -9.36% | ||
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -1.70% |
| 2025-08-11 | 2025-08-11 | Quarterly Result Announcement | NA | -3.59% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | -6.14% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -12.62% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -7.93% |
| 2023-12-21 | 2023-12-21 | Extraordinary General Meeting | NA | -10.17% |
Bal Pharma Competitors Screener - Peer Comparison
Screen BALPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 424,634 | 39.93 | 54,729 | 9.71% | 10,980 | 49.55 |
| Divis Laboratories | 172,860 | 69.20 | 9,712 | 18.67% | 2,191 | 56.33 |
| Torrent Pharmaceuticals | 129,151 | 60.10 | 11,539 | 6.99% | 1,911 | 61.47 |
| Cipla | 122,205 | 22.55 | 28,410 | 7.12% | 5,291 | 49.47 |
| Dr Reddys Laboratories | 107,114 | 18.60 | 33,741 | 16.73% | 5,725 | 60.05 |
| Lupin | 97,120 | 22.34 | 22,910 | 13.74% | 3,306 | 65.28 |
| Zydus Life Science | 92,392 | 18.40 | 23,511 | 18.55% | 4,615 | 40.07 |
| Mankind Pharma | 90,241 | 50.59 | 12,744 | 20.90% | 2,007 | 45.53 |
| Aurobindo Pharma | 71,119 | 20.79 | 32,346 | 9.43% | 3,484 | 59.88 |
| Alkem Laboratories | 67,243 | 27.59 | 13,458 | 3.70% | 2,216 | 49.80 |
Bal Pharma Company Announcements - News Screener
Screen BALPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-12 | Unaudited Financial Results For The Quarter Ended 30.09.2025 | View |
| 2025-11-12 | Board Meeting Outcome for Outcome Of The Board Meeting_12.11.2025 | View |
| 2025-11-07 | Update On The Outcome Of The Board Meeting Held On 11.08.2025 | View |
| 2025-11-04 | Board Meeting Intimation for Unaudited Financial Results | View |
| 2025-10-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-30 | Announcement under Regulation 30 (LODR)-Change in Directorate | View |
| 2025-09-26 | Closure of Trading Window | View |
| 2025-09-25 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-09-02 | Reg. 34 (1) Annual Report. | View |
| 2025-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-12 | Corporate Action-Fixes Record Date For Dividend. | View |
| 2025-08-11 | Unaudited Financial For The Quarter Ended 30.06.2025. | View |
| 2025-08-11 | Board Meeting Outcome for Outcome Of The Board Meeting | View |
| 2025-07-29 | Board Meeting Intimation for Inter Alia Take On Record And Approve The Unaudited Financial Results For The Quarter Ended 30.06.2025. | View |
| 2025-07-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-07-03 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-07-02 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-06-30 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |